Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

INTRODUCTION: Dupilumab, a fully human anti-IL-4Rα monoclonal antibody, inhibits signaling of both interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the EU, USA, and other countries for the treatment of adults with inadequately controlled m...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Adv Ther
Päätekijät: Busse, William W., Maspero, Jorge F., Rabe, Klaus F., Papi, Alberto, Wenzel, Sally E., Ford, Linda B., Pavord, Ian D., Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Akinlade, Bolanle, Eckert, Laurent, Chao, Jingdong, Graham, Neil M. H., Teper, Ariel
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Healthcare 2018
Aiheet:
Study Protocol
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5960488/
https://ncbi.nlm.nih.gov/pubmed/29725983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-018-0702-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia